Therapeutic use of HMG-CoA reductase inhibitors: Current practice and future perspectives

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 11, 2004, Pages 1553-1566

  Cattaneo, Dario ^a,b   Baldelli, Sara ^a,b   Merlini, Simona ^a,b   Zenoni, Stefania ^a,b   Perico, Norberto ^a,b   Remuzzi, Giuseppe ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Bone formation; Dyslipidaemia; HMG CoA reductase inhibitors; Immunomodulation; Neoplasm; Neurodegenerative disease; Prenylated protein

Indexed keywords

6 [2 [4 (4 FLUOROPHENYL) 2 ISOPROPYL 6 PHENYL 3 PYRIDYL]VINYL] 3,4,5,6 TETRAHYDRO 4 HYDROXY 2H PYRAN 2 ONE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ASCORBIC ACID; ATORVASTATIN; BERVASTATIN; CARDIOVASCULAR AGENT; CARVASTATIN; CERIVASTATIN; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COMPACTIN; CRILVASTATIN; DALVASTATIN; DIHYDROCOMPACTIN; FENOFIBRATE; FLUINDOSTATIN; GLENVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; ML 236; PANTETHINE; PITAVASTATIN; PRAVASTATIN; RIBOFLAVIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELOSTATIN; VITAMIN;

AUTOIMMUNE DISEASE; BONE DEFECT; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CLINICAL TRIAL; CYTOLOGY; DEGENERATIVE DISEASE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG USE; ENDOTHELIUM LESION; HEMATURIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID BLOOD LEVEL; LIVER TOXICITY; METABOLIC BONE DISEASE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NERVE CELL LESION; OSTEOPOROSIS; PATENT; PLEIOTROPY; PRENYLATION; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; SMOOTH MUSCLE FIBER;

EID: 8444245524     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.11.1553     Document Type: Review

References (56)

1. ROSAMOND WD, CHAMBLESS LE, FOLSOM AR et al.: Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N. Engl. J. Med. (1998) 339 13):861-867.
2. MURRAY CJ, LOPEZ AD: Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet (1997) 349(9063):1436-1442.
3. LEVINE GN, KEANEY JF JR, VITA JA: Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N. Engl. J. Med. (1995) 332(8):512-521.
4. CORESH J, KWITEROVICH PO JR. Small, dense low-density lipoprotein particles and coronary heart disease risk: a clear association with uncertain implications. JAMA (1996) 276 11):914-915.
5. ORAM JF, YOKOYAMA S: Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J. Lipid Res. (1996) 37 12):2473-2491.
6. WILSON PW, D'AGOSTINO RB, LEVY D et al.: Prediction of coronary heart disease using risk factor categories. Circulation (1998) 97(23):1837-1847.
7. ENDO A, KURODA M, TSUJITA Y: ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J. Antibiot. (1976) 29(12):1346-1348.
8. MABUCHI H, HABA T, TATAMI R et al.: Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N. Engl. J. Med. (1981) 305(9 ):478-482.
9. TOBERT JA: Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov. (2003) 2 7):517-526.
10. GRUNDI SM, CLEAMAN JI, MERZ CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 110: 27-239.
11. MARON DJ, FAZIO S, LINTON MF: Current perspectives on statins. Circulation (2000) 101(11):207-213.
12. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7-22.
13. BELLOSTA S, FERRI N, BERNINI F, PAOLETTI R, CORSINI A. Non-lipid-related effects of statins. Ann. Med. (2000) 32 3):164-176.
14. BOLEGO C, POLI A, CIGNARELLA A, CATAPANO AL, PAOLETTI R: Novel statins: pharmacological and clinical results. Cardiovasc. Drugs Ther. (2002) 16(3):251-257.
15. ROSENSON RS: Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Rev. Cardiovasc. Ther. (2003) 1(4):495-505.
16. HUNNINGHAKE DB, STEIN EA, BAYS HE et al.: Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron. Artery Dis. (2004) 15 3):115-123.
17. WOLFE SM: Dangers of rosuvastatin identified before and after FDA approval. Lancet (2004) 363(9427):2189-2190.
18. SIDAWAY JE, DAVIDSON RG, MCTAGGART F et al.: Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J. Am. Soc. Nephrol. (2004) 15(9):2258-2265.
19. VIDT DG, CRESSMAN MD, HARRIS S, PEARS JS, HUTCHINSON HG: Rosuvastatin-induced arrest in progression of renal disease. Cardiology (2004) 102(2):52-60.
20. KAJINAMI K, TAKEKOSHI N, SAITO Y: Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc. Drug Rev. (2003) 21(3):199-215.
21. WAJIMA T, MAKITA S, OSHIMA K: Effects of HR780, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits and cholesterol-fed rabbits. Pharmacology (2004) 70(3):123-129.
22. WAJIMA T, MAKITA S, OSHIMA K: Direct vascular effects of HR780, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Clin. Exp. Pharmacol. Physiol. (2003) 30(12):958-962.
23. ENDO A, TSUJITA Y, KURODA M, TANZAWA K: Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur. J. Biochem. (1977) 77(1):31-36
24. BROWN MS, GOLDSTEIN JL: A receptor-mediated pathway for cholesterol homeostasis. Science (1986) 232(4746):34-47.
25. MARAIS AD, NAOUMOVA RP, FIRTH JC, PENNY C, NEUWIRTH CK THOMPSON GR. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J. Lipid Res. (1997) 38(10):2071-2078.
26. BROUSSEAU ME, SCHAEFER EJ, WOLFE ML et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. (2004) 350(15):1505-1515.
27. MIYAZAKI A, SAKAI M, SAKAMOTO Y, HORIUCHI S: Acyl-coenzyme A: cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis. Curr. Opin. Investig. Drugs (2003) 4(9):1095-1099.
28. BORGHI C: Interactions between hypercholesterolemia and hypertension: implications for therapy. Curr. Opin. Nephrol. Hypertens (2002) 11(5):489-496.
29. BORGHI C, DORMI A, VERONESI M, IMMORDINO V, AMBROSIONI E: Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension. J. Clin. Hypertens. (2002) 4 4):277-285.
30. VAN DOKKUM RP, HENNING RH, DE ZEEUW D. Statins: cholesterol, blood pressure and beyond. J. Hypertens. (2002) 20 12):2351-2353.
31. BROWN BG, ZHAO XQ: Importance of endothelial function in mediating the benefits of lipid-lowering therapy. Am. J. Cardiol. (1998) 82(10B):49T-52T.
32. LAUFS U, LA FATA V, PLUTZKY J, LIAO JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation (1998) 97(12):1129-1135.
33. WASSMANN S, LAUFS U, BAUMER AT et al.: Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol. Pharmacol. (2001) 59(3):646-654.
34. KIM SI, HAN DC, LEE HB: Lovastatin inhibits transforming growth factor-β1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J. Am. Soc. Nephrol. (2000) 11(1 ):80-87.
35. ZOJA C, CORNA D, CAMOZZI D et al.: How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J. Am. Soc. Nephrol. (2002) 13(12):2898-2908.
36. ZAMRINI E, MCGWIN G, ROSEMAN JM: Association between statin use and Alzheimer's disease. Neuroepidemiology (2004) 23 1-2):94-98.
37. STUVE O, YOUSSEF S, STEINMAN L, ZAMVIL SS: Statins as potential therapeutic agents in neuroinflammatory disorders. Curr. Opin. Neurol. (2003) 16(3):393-401.
38. MUNDY G, GARRETT R, HARRIS S et al.: Stimulation of bone formation in vitro and in rodents by statins. Science (1999) 286(5446):1946-1949.
39. GARRETT IR, MUNDY GR: The role of statins as potential targets for bone formation. Arthritis Res. (2002) 4 4):237-240.
40. BAUER DC, MUNDY GR, JAMAL SA et al.: Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch. Intern. Med. (2004) 164(2):146-152.
41. LACROIX AZ, CAULEY JA, PETTINGER M et al.: Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann. Intern. Med (2003) 139(2):97-104.
42. PALINSKI W, TSIMIKAS S: Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J. Am. Soc. Nephrol. (2002) 13(6):1673-1681.
43. KWAK B, MULHAUPT F, MYIT S, MACH F: Statins as a newly recognized type of immunomodulator. Nat. Med. (2000) 6 12):1399-1402.
44. WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7 6):687-692.
45. CHAN KK, OZA AM, SIU LL. The statins as anticancer agents: Clin. Cancer Res. (2003) 9(1):10-19.
46. GRAAF MR, BEIDERBECK AB, EGBERTS AC, RICHEL DJ, GUCHELAAR HJ: The risk of cancer in users of statins. J. Clin. Oncol. (2004) 22(12):2388-2394.
47. POYNTER JN, RENNERT G, BONNER D, RENNERT HS, GREENSON JK, GRUBER SB: HMG-CoA reductase inhibitors and the risk of cancer. 40th American Society of Clinical Oncology Meeting. New Orleans, USA (2004).
48. BELL IM: Inhibitors of protein prenylation 2000. Expert Opin. Ther. Patents (2000) 10(19):1813-1831.
49. KARAMOUZIS MV, PAPAVASSILIOU AG: COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet? Expert Opin. Investig. Drugs (2004) 13(4):359-372.
50. BALLANTYNE CM, CORSINI A, DAVIDSON MH et al.: Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med (2003) 163(5):553-564.
51. STAFFA JA, CHANG J, GREEN L: Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. (2002) 346(7 ):539-540.
52. SORELLE R. Baycol withdrawn from market. Circulation (2001) 104(8):E9015-E9016.
53. NO AUTHORS LISTED: OTC statins: a bad decision for public health. Lancet (2004) 363(9422):1659.
54. MOOSMANN B, BEHL C. Selenoprotein synthesis and side-effects of statins: Lancet (2004) 363(9412):892-994.
55. McKILLOP T: The statin wars. Lancet (2003) 362 9394):1498.
56. MCKENNEY JM: Optimizing LDL-C lowering with statins. Am. J. Ther. (2004) 11(1):54-55.